Vancouver, British Columbia – July 23rd, 2019 – Qu Biologics Inc. (Qu), a biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a unique platform of microbial-based immunotherapies designed to restore… Read More
Results demonstrate that AB-506 is a potent capsid inhibitor Phase 1a/1b clinical trial to continue with the enrollment of further cohorts Conference call and webcast scheduled today at 4:45 pm ET… Read More
VANCOUVER, British Columbia and MENLO PARK, Calif., July 10, 2019 /PRNewswire/ — DelMar Pharmaceuticals, Inc. (NASDAQ: DMPI) (“DelMar” or the “Company”), a biopharmaceutical company focused on the development of novel cancer therapies,… Read More
Arbutus to receive $20 million in gross proceeds before advisory fees while retaining significant downstream economics Runway extended with non-dilutive capital WARMINSTER, Pa., July 02, 2019 (GLOBE NEWSWIRE) — Arbutus Biopharma Corporation (Nasdaq: ABUS), an industry-leading… Read More
VANCOUVER, British Columbia and MENLO PARK, Calif., June 27, 2019 /PRNewswire/ — DelMar Pharmaceuticals, Inc. (NASDAQ: DMPI) (“DelMar” or the “Company”), a biopharmaceutical company focused on the development and commercialization… Read More
